Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free REVB Stock Alerts

Revelation Biosciences (REVB) Competitors

Revelation Biosciences logo
$1.08 +0.05 (+4.33%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

REVB vs. CTXR, QCLS, CYCN, LEXX, and BFRI

Should you buy Revelation Biosciences stock or one of its competitors? MarketBeat compares Revelation Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revelation Biosciences include Citius Pharmaceuticals (CTXR), Mymd Pharmaceuticals (QCLS), Cyclerion Therapeutics (CYCN), Lexaria Bioscience (LEXX), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry.

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Citius Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Citius Pharmaceuticals' return on equity of -61.09% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -61.09% -35.36%
Revelation Biosciences N/A -107.65%-87.98%

In the previous week, Revelation Biosciences had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.63 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Citius Pharmaceuticals Very Positive
Revelation Biosciences Positive

Citius Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 848.77%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius PharmaceuticalsN/AN/A-$37.43M-$2.13N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Citius Pharmaceuticals beats Revelation Biosciences on 10 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Mymd Pharmaceuticals?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Revelation Biosciences (NASDAQ:REVB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mymd Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Mymd Pharmaceuticals has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Revelation Biosciences had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.63 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Mymd Pharmaceuticals Very Positive
Revelation Biosciences Positive

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mymd PharmaceuticalsN/AN/A-$11.63M-$20.69N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

Mymd Pharmaceuticals' return on equity of -76.40% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Mymd PharmaceuticalsN/A -76.40% -35.10%
Revelation Biosciences N/A -107.65%-87.98%

Summary

Mymd Pharmaceuticals and Revelation Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Revelation Biosciences compare to Cyclerion Therapeutics?

Revelation Biosciences (NASDAQ:REVB) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Cyclerion Therapeutics has higher revenue and earnings than Revelation Biosciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
Cyclerion Therapeutics$2.07M7.80-$3.53M-$1.36N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Revelation Biosciences had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.63 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Revelation Biosciences Positive
Cyclerion Therapeutics Very Positive

Revelation Biosciences has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Revelation Biosciences has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -62.10% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
Cyclerion Therapeutics -170.11%-62.10%-55.14%

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Cyclerion Therapeutics beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Lexaria Bioscience presently has a consensus price target of $1.50, suggesting a potential upside of 162.24%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Lexaria Bioscience is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexaria Bioscience
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revelation Biosciences' return on equity of -107.65% beat Lexaria Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Lexaria BioscienceN/A -173.93% -138.79%
Revelation Biosciences N/A -107.65%-87.98%

Lexaria Bioscience has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Revelation Biosciences has lower revenue, but higher earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$710K19.97-$11.90M-$0.47N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 2 articles in the media. Revelation Biosciences' average media sentiment score of 0.63 beat Lexaria Bioscience's score of -0.57 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Lexaria Bioscience Negative
Revelation Biosciences Positive

Summary

Lexaria Bioscience beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Biofrontera?

Revelation Biosciences (NASDAQ:REVB) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Revelation Biosciences has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Revelation Biosciences has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
Biofrontera$41.71M0.33-$10.54M-$0.97N/A

In the previous week, Biofrontera had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for Revelation Biosciences. Biofrontera's average media sentiment score of 0.89 beat Revelation Biosciences' score of 0.63 indicating that Biofrontera is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biofrontera
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biofrontera
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Revelation Biosciences has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Revelation Biosciences' return on equity of -107.65% beat Biofrontera's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
Biofrontera -25.66%-515.34%-53.91%

Summary

Biofrontera beats Revelation Biosciences on 9 of the 14 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVB vs. The Competition

Export
MetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.24M$3.67B$6.78B$12.65B
Dividend YieldN/A2.19%2.68%8.43%
P/E Ratio-0.0321.4827.1324.40
Price / SalesN/A327.86525.2891.46
Price / CashN/A143.6648.5959.39
Price / Book0.858.5510.856.33
Net Income-$8.91M$23.88M$3.59B$331.45M
7 Day Performance10.71%-2.84%-1.34%0.18%
1 Month Performance9.47%5.93%2.96%-0.72%
1 Year Performance-90.55%52.58%28.93%20.53%

Revelation Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVB
Revelation Biosciences
1.2891 of 5 stars		$1.09
+4.3%		N/A-90.5%$4.24MN/AN/A10
CTXR
Citius Pharmaceuticals
2.7747 of 5 stars		$0.56
-4.5%		$5.00
+797.2%		-68.1%$15.30MN/AN/A20
QCLS
Mymd Pharmaceuticals
0.6068 of 5 stars		$3.66
-0.3%		N/AN/A$15.26MN/AN/A6
CYCN
Cyclerion Therapeutics
0.9737 of 5 stars		$3.47
-0.3%		N/A+16.1%$15.03M$2.07MN/A30
LEXX
Lexaria Bioscience
1.7931 of 5 stars		$0.61
+14.1%		$1.50
+147.9%		-29.6%$15.00M$710KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:REVB) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel